The inhibitory receptor CD94/NKG2A on CD8
Adult
Aged
Aged, 80 and over
Animals
Biomarkers, Tumor
/ analysis
CD8-Positive T-Lymphocytes
/ drug effects
Cell Line, Tumor
Coculture Techniques
Colorectal Neoplasms
/ drug therapy
Female
Histocompatibility Antigens Class I
/ analysis
Humans
Immune Checkpoint Inhibitors
/ therapeutic use
Immunohistochemistry
Lymphocytes, Tumor-Infiltrating
/ drug effects
Male
Mice
Microsatellite Instability
Middle Aged
Molecular Targeted Therapy
NK Cell Lectin-Like Receptor Subfamily C
/ analysis
NK Cell Lectin-Like Receptor Subfamily D
/ analysis
Prospective Studies
Retrospective Studies
Tissue Array Analysis
Young Adult
beta 2-Microglobulin
/ analysis
HLA-E Antigens
Journal
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
28
03
2019
accepted:
14
06
2019
revised:
13
06
2019
pubmed:
15
8
2019
medline:
26
1
2021
entrez:
15
8
2019
Statut:
ppublish
Résumé
We previously demonstrated that HLA-E/β2m overexpression by tumor cells in colorectal cancers is associated with an unfavorable prognosis. However, the expression of its specific receptor CD94/NKG2 by intraepithelial tumor-infiltrating lymphocytes, their exact phenotype and function, as well as the relation with the molecular status of colorectal cancer and prognosis remain unknown. Based on a retrospective cohort of 234 colorectal cancer patients, we assessed the expression of HLA-E, β2m, CD94, CD8, and NKp46 by immunohistochemistry on tissue microarray. The expression profile of HLA-E/β2m on tumor cells and the density of tumor-infiltrating lymphocytes were correlated to the clinicopathological and molecular features (Microsatellite status, BRAF and RAS mutations). Then, from the primary tumors of 27 prospective colorectal cancers, we characterized by multiparameter flow cytometry the nature (T and/or NK cells) and the co-expression of the inhibitory NKG2A or activating NKG2C chain of ex vivo isolated CD94
Identifiants
pubmed: 31409873
doi: 10.1038/s41379-019-0322-9
pii: S0893-3952(22)00916-4
doi:
Substances chimiques
B2M protein, human
0
Biomarkers, Tumor
0
Histocompatibility Antigens Class I
0
Immune Checkpoint Inhibitors
0
KLRC1 protein, human
0
KLRD1 protein, human
0
NK Cell Lectin-Like Receptor Subfamily C
0
NK Cell Lectin-Like Receptor Subfamily D
0
beta 2-Microglobulin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
468-482Références
Pagès F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Eng J Med. 2005;353:2654–66.
doi: 10.1056/NEJMoa051424
Galon J. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–4.
doi: 10.1126/science.1129139
Reissfelder C, Stamova S, Gossmann C, et al. Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis. J Clin Invest. 2015;125:1364–1364.
doi: 10.1172/JCI81442
Pagès F, Mlecnik B, Marliot F, et al. International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391:2128–39.
doi: 10.1016/S0140-6736(18)30789-X
Mlecnik B, Bindea G, Angell HK, et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity. 2016;44:698–711.
doi: 10.1016/j.immuni.2016.02.025
Banerjea A, Hands RE, Powar MP, et al. Microsatellite and chromosomal stable colorectal cancers demonstrate poor immunogenicity and early disease recurrence. Colorectal Dis. 2009;11:601–8.
doi: 10.1111/j.1463-1318.2008.01639.x
Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21:1350–6.
doi: 10.1038/nm.3967
Marisa L, de Reyniès A, Duval A, et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med. 2013;10:e1001453.
doi: 10.1371/journal.pmed.1001453
Llosa NJ, Cruise M, Tam A, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5:43–51.
doi: 10.1158/2159-8290.CD-14-0863
Ott E, Bilonda L, Dansette D, et al. The density of Tbet+ tumor-infiltrating T lymphocytes reflects an effective and druggable preexisting adaptive antitumor immune response in colorectal cancer, irrespective of the microsatellite status. OncoImmunology 2019;8:e1562834.
Wischhusen J, Friese MA, Mittelbronn M, et al. HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: implications for immune escape in vivo. J Neuropathol Exp Neurol. 2005;64:523–8.
doi: 10.1093/jnen/64.6.523
Derré L, Corvaisier M, Charreau B, et al. Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells. J Immunol. 2006;177:3100–7.
doi: 10.4049/jimmunol.177.5.3100
Levy EM, Bianchini M, Von Euw EM, et al. Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer. Int J Oncol. 2008;32:633–41.
pubmed: 18292941
Braud VM, Allan DSJ, O’Callaghan CA, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 1998;391:795–9.
doi: 10.1038/35869
Borrego F, Masilamani M, Marusina AI, et al. The CD94/NKG2 family of receptors: from molecules and cells to clinical relevance. Immunol Res. 2006;35:263–78.
doi: 10.1385/IR:35:3:263
Bossard C, Bézieau S, Matysiak-Budnik T, et al. HLA-E/β2 microglobulin overexpression in colorectal cancer is associated with recruitment of inhibitory immune cells and tumor progression. Int J Cancer. 2012;131:855–63.
doi: 10.1002/ijc.26453
Wang R, Wang M-J, Ping J. Clinicopathological features and survival outcomes of colorectal cancer in young versus elderly: a population-based cohort study of SEER 9 registries data (1988–2011). Medicine. 2015;94:e1402.
doi: 10.1097/MD.0000000000001402
Suraweera N, Duval A, Reperant M, et al. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterol. 2002;123:1804–11.
doi: 10.1053/gast.2002.37070
Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261–8.
doi: 10.1093/jnci/djh034
Gervois N, Labarriere N, Le Guiner S, et al. High avidity melanoma-reactive cytotoxic T lymphocytes are efficiently induced from peripheral blood lymphocytes on stimulation by peptide-pulsed melanoma cells. Clin Cancer Res. 2000;6:1459–67.
pubmed: 10778978
Lee MS, Menter DG, Kopetz S. Right versus left colon cancer biology: integrating the consensus molecular subtypes. J Natl Compr Canc Netw. 2017;15:411–9.
doi: 10.6004/jnccn.2017.0038
Mandrekar JN, Mandrekar SJ, Cha SS. Cutpoint determination methods in survival analysis using SAS®. In: Proceedings of the 28th SAS Users Group International Conference (SUGI) 2003, Paper 261-28.
André P, Denis C, Soulas C, et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell 2018;175:1731–1743.e13.
doi: 10.1016/j.cell.2018.10.014
Zeestraten ECM, Reimers MS, Saadatmand S, et al. Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients. Br J Cancer. 2014;110:459–68.
doi: 10.1038/bjc.2013.696
Gooden M, Lampen M, Jordanova ES, et al. HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+ T lymphocytes. Proc Natl Acad Sci USA. 2011;108:10656–61.
doi: 10.1073/pnas.1100354108
Gooden MJM, van Hall T. Infiltrating CTLs are bothered by HLA-E on tumors. Oncoimmunol. 2012;1:92–3.
doi: 10.4161/onci.1.1.17961
van Montfoort N, Borst L, Korrer MJ, et al. NKG2A blockade potentiates CD8 T cell immunity induced by cancer vaccines. Cell. 2018;175:1744–1755.e15.
doi: 10.1016/j.cell.2018.10.028
Halama N, Braun M, Kahlert C, et al. Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin Cancer Res. 2011;17:678–89.
doi: 10.1158/1078-0432.CCR-10-2173
Sheu B-C, Chiou S-H, Lin H-H, et al. Up-regulation of inhibitory natural killer receptors CD94/NKG2A with suppressed intracellular perforin expression of tumor-infiltrating CD8+ T lymphocytes in human cervical carcinoma. Cancer Res. 2005;65:2921–9.
doi: 10.1158/0008-5472.CAN-04-2108
Chang W-C, Huang S-C, Torng P-L, et al. Expression of inhibitory natural killer receptors on tumor-infiltrating CD8+ T lymphocyte lineage in human endometrial carcinoma. Int J Gynecol Cancer. 2005;15:1073–80.
doi: 10.1111/j.1525-1438.2005.00264.x
Zhang L, Zhao Y, Dai Y, et al. Immune landscape of colorectal cancer tumor microenvironment from different primary tumor location. Front Immunol. 2018;9:1578.
doi: 10.3389/fimmu.2018.01578
Malmberg K-J, Levitsky V, Norell H, et al. IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J Clin Invest. 2002;110:1515–23.
doi: 10.1172/JCI0215564
Chen D, Li L, Zhang X, et al. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: a meta-analysis. Medicine. 2018;97:e0097.
doi: 10.1097/MD.0000000000010097